Innocare Pharma
InnoCare Pharma Ltd is a Chinese clinical-stage biopharmaceutical enterprise specializing in the discovery, development, and commercialization of innovative targeted therapies and immunotherapies for the treatment of cancer and autoimmune diseases, prominently featuring novel Bruton's tyrosine kinase (BTK) inhibitors such as orelabrutinib. The company conducts advanced clinical trials evaluating small molecule drugs and biological therapies designed to combat hematological malignancies, solid tumors, and autoimmune disorders. Its core business operations encompass biopharmaceutical research, clinical trial execution, drug formulation development, and commercial pharmaceutical strategy. As a commercial-stage biotechnology enterprise, the company generates revenue through pharmaceutical product sales and collaborative research licensing agreements. InnoCare Pharma holds a leading market position in targeted oncology and immunology therapeutics in China. The company is headquartered in Beijing, China, with corporate registration in the Cayman Islands, and its shares trade on the Stock Exchange of Hong Kong.
4 of the funds FundTelligence covers report a position in Innocare Pharma.
- Legal name
- Innocare Pharma Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 4
Funds holding Innocare Pharma
- BNP China Equity — BNP Paribas · 0.64 % (full portfolio disclosed, June 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.06 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)